NeuroVive’s objective is to design pharmaceuticals that preserve the integrity and function of mitochondria for indications where there is a great unmet medical need. NeuroVive is continuously engaged in the vibrant mitochondrial science community as well as the world of investors and potential partners.
Redeye Digital Investor Forum, 31 March, 2020.
Erik Penser Bank Bolagsdag, 12 March, 2020, Stockholm, Sweden.
Stockholm Corporate Finance 12th Life Science seminar, 11 March, 2020.
Aktiespararna’s Aktiedagen Lund, 28 January 2020, Lund, Sweden.